Application of medicine for preventing and treating deafness in preparation of medicine for preventing and treating chemical liver injury
By adjusting the proportions of ginseng, astragalus, turmeric, kudzu root, platycodon, and licorice, a traditional Chinese medicine preparation was developed for the prevention and treatment of chemically induced liver injury. This solution addresses the problem that existing traditional Chinese medicine compositions cannot prevent and treat chemically induced liver injury, and achieves the effect of significantly reducing ALT and AST levels and improving liver tissue damage.
Patent Information
- Application Number
- CN202410972326.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-19
AI Technical Summary
Existing Chinese herbal compositions used to prevent and treat drug-induced hearing loss and age-related hearing loss are ineffective in preventing and treating chemical-induced liver damage, and lack therapeutic applications for chemical-induced liver damage.
The proportions of ginseng, astragalus, turmeric, kudzu root, platycodon, and licorice are adjusted to a specific ratio and made into granules, tablets, capsules, or oral liquids for the prevention and treatment of chemically induced liver injury. By invigorating qi and strengthening the body, invigorating the spleen and soothing the liver, and removing blood stasis and promoting blood circulation, ALT and AST levels are significantly reduced and liver tissue morphology is improved.
It significantly reduced ALT and AST levels in a mouse model of chemically induced liver injury, improved liver tissue morphology, and alleviated chemically induced liver injury, especially showing significant effects on liver injury induced by cisplatin, carbon tetrachloride, and alcohol.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004953589900000011
Abstract
Description
Technical Field
[0001] The present invention relates to a medical preparation, in particular to a pharmaceutical preparation containing an undetermined structure from traditional Chinese medicine. The pharmaceutical preparation is suitable for preventing and treating chemical liver damage. Background Art
[0002] Liver injury is a pathological condition common to all types of liver diseases and poses a serious threat to human health. It is reported that approximately 3.5% of deaths worldwide are directly related to liver injury. Among them, chemical liver injury is induced by a variety of factors, including drugs, alcohol, chemical toxins, and viruses. Chemical liver injury develops rapidly, can cause significant liver function abnormalities, and can lead to complications such as liver failure, hepatic encephalopathy, and acute kidney injury. It is one of the causes of high mortality (CRISMALE JF, FRIEDMAN SL. Acute liver injury and decompensated cirrhosis [J]. The medical clinics of North America, 2020, 104 (4): 647-662). At present, traditional Chinese medicine with multi-pathway, multi-target, and multi-indication characteristics has shown significant efficacy in the treatment of chemical liver injury, providing an important source of raw materials for the development of new liver protection drugs. Studies have shown that traditional Chinese medicine can play an anti-liver injury role through anti-inflammatory, anti-oxidative, apoptosis inhibition and intestinal flora regulation (Wang Guiqiu, Liu Xueping, Deng Shuwu, et al. Research progress on the mechanism of action of traditional Chinese medicine in the treatment of acute liver injury [J]. Journal of Guangxi Medical University, 2023, 40(11): 1921-1927.). It is usually determined whether liver damage has occurred by testing plasma AST, ALT and other indicators and pathological histological observation.
[0003] In clinical practice, although drugs such as N-acetylcysteine, glucocorticoids, silymarin and bifendate have certain therapeutic effects on liver injury, their efficacy and safety have certain limitations (HU C. Transplantation of mesenchymal stem cells and their derivatives effectively promotes liver regeneration to at-tenuate acetaminophen-induced liver injury [J]. Stem Cell Res Ther, 2020, 11 (1): 88.). As a temporary liver support system, artificial liver is limited in its application due to its complex equipment and large size. Liver transplantation is currently the only effective means, but its application is limited by organ donor shortage, immune rejection and high medical costs (ZHANG J. Stem cell therapy and tissue engineering strategies using cell aggregates and decellularized scaffolds for the rescue of liver failure [J]. J Tissue Eng, 2021, 12: 2041731420986711.).
[0004] Chemical liver injury is a modern medical term. There is no direct record of "liver injury" in Chinese medicine. Chemical liver injury can be classified into the categories of "alcohol injury", "flank pain", "alcohol addiction", "drug poison", "swelling" and "jaundice" in traditional Chinese medicine according to its clinical manifestations. According to traditional Chinese medicine theory, chemical poisons, hepatotoxic drugs or excessive alcohol are toxic evils, which are the basic factors causing the disease. In terms of treatment, the basic principles of traditional Chinese medicine prescriptions are to examine the symptoms and seek the cause, combine syndrome differentiation and treatment with disease differentiation and treatment, and combine the local with the whole. Traditional Chinese medicine believes that the causes of liver injury can be divided into internal and external aspects. The internal cause is the lack of positive energy, and the external cause is the invasion of "toxic evil" by the body. The location of the disease is not limited to the liver, but also involves the spleen, stomach, gallbladder, kidney and other internal organs. The spleen and stomach are dysfunctional, the liver and gallbladder are abnormal, and there are qi stagnation, dampness obstruction, heat depression, and blood stasis, resulting in clinical manifestations such as flank pain, jaundice, swelling, and accumulation. Therefore, in terms of treatment, the treatment methods can be to invigorate qi and strengthen the body, strengthen the spleen and liver, and remove blood stasis.
[0005] The invention patent application with the publication number of CN 117180386A discloses a Chinese medicine composition for preventing and treating drug-induced deafness and presbycusis, wherein the effective ingredients are made of the following raw materials in percentage by weight: 9-13% of ginseng, 31-35% of astragalus, 9-13% of turmeric, 20-24% of kudzu root, 9-13% of platycodon, and 9-13% of liquorice. At the same time, the above patent application also discloses the following contents: ginseng and astragalus are the main ingredients, the former greatly replenishes the qi of the five internal organs, especially the spleen and lung, and the latter replenishes qi and raises yang, and the combination of the two greatly replenishes the vital energy, makes the clear qi rise, and nourishes the ear; turmeric and kudzu root are the subordinate ingredients, turmeric activates blood circulation and qi, removes blood stasis and dredges the collaterals, and kudzu root dredges the meridians and activates the collaterals, helps the main ingredient to raise the clear yang and clear the ear; platycodon is the auxiliary ingredient, which opens and clears the lung qi, clears the head and eyes, and carries the medicine upward; liquorice is the messenger ingredient, which replenishes the spleen and qi, clears away heat and detoxifies, and harmonizes the various medicines. The combination of these medicines can nourish the spleen and lungs, raise the clear qi, remove blood stasis and dredge the meridians, and restore hearing. However, drug-induced deafness and presbycusis are two different diseases from chemical liver injury, and their pathogenesis and clinical symptoms are completely different. Therefore, ordinary technicians in this field cannot infer that the Chinese medicine composition described in the above patent application also has the therapeutic use of preventing and treating chemical liver injury. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide a new use of a Chinese medicine composition for preventing and treating deafness, that is, a new application in pharmaceutical manufacturing.
[0007] The new use of the above-mentioned Chinese medicine composition for preventing and treating deafness is:
[0008] The application of drugs for preventing and treating drug-induced deafness and presbycusis in the preparation of drugs for preventing and treating chemical liver damage, wherein:
[0009] The active ingredients of the drug for preventing and treating chemical liver damage are made of the following raw materials in percentage by weight:
[0010] Ginseng 9-13%, Astragalus 31-35%, Turmeric 9-13%, Pueraria 20-24%, Platycodon 9-13%, Licorice 9-13%;
[0011] The chemical liver injury is chemical liver injury caused by cisplatin, carbon tetrachloride or alcohol.
[0012] In the above application, the raw materials and their dosage ranges used in the drug for preventing and treating drug-induced deafness and presbycusis are the same as those in the patent application with authorization announcement number CN 117180386 B.
[0013] The application of the present invention, wherein the optimal ratio of the raw material medicine is:
[0014] Ginseng 11.1%, Astragalus 33.3%, Turmeric 11.1%, Pueraria lobata 22.2%, Platycodon 11.1%, Licorice 11.2%.
[0015] The application of the present invention, wherein the active ingredient is prepared by the following method:
[0016] (1) placing the raw drug in a traditional Chinese medicine frying pan, adding 8-12 times water to soak for 1-2 hours, boiling over high heat, then decocting over low heat for 1-2 hours, then filtering and collecting the first decoction;
[0017] (2) Add 6-10 times more water to the residue, boil over high heat, then simmer over low heat for 40-60 min, filter, and collect the second decoction;
[0018] (3) The two decoctions are combined, evaporated and concentrated to a concentrate with a concentration of 1 g crude drug / mL, and dried to obtain the active ingredient.
[0019] In the application described in the present invention, the drug for preventing and treating chemical liver damage is a conventional granule, tablet, capsule or oral liquid.
[0020] The application described in the present invention, wherein the drug for preventing and treating chemical liver injury can invigorate qi and strengthen the body, strengthen the spleen and soothe the liver, remove blood stasis and activate blood circulation, can significantly reduce ALT and AST levels, improve liver tissue morphological damage, and has a significant effect in preventing and treating chemical liver injury.
[0021] In order to better understand the beneficial effects of the present invention, the following will further illustrate the invention through examples and animal experiments. Study on the effect of preventing and treating chemical liver damage (animal experiment)
[0023] 1 Experimental Materials
[0024] 1.1 Experimental animals: SPF-grade male ICR mice (25-30 g) were purchased from Guangdong Medical Experimental Animal Center. After passing the quality inspection of Guangdong Medical Experimental Animal Center, they were allowed to enter the Experimental Animal Center of Guangdong Pharmaceutical University for breeding. The breeding temperature was controlled at 20-25°C, the humidity was 40%-60%, and the light and dark were alternated for 12 hours. The water and bedding were changed in time according to regulations. The experiment strictly complied with the relevant regulations on animal welfare ethics and protection of the country and Guangdong Province. The animal experiment number is SPF2022379.
[0025] 1.2 Experimental materials: Cisplatin injection, purchased from Qilu Pharmaceutical Co., Ltd.; 1% saline, purchased from Jinkelong Biotechnology Co., Ltd.; pentobarbital, purchased from Chengdu Grecia Chemical Technology Co., Ltd.; bifendate dripping pills, purchased from Beijing Union Pharmaceutical Factory; paraformaldehyde, purchased from Shanghai McLean Biochemical Technology Co., Ltd.; carbon tetrachloride, purchased from Shanghai McLean Biochemical Technology Co., Ltd.; anhydrous ethanol, purchased from Shanghai McLean Biochemical Technology Co., Ltd.; alanine aminotransferase test kit and aspartate aminotransferase assay kit, purchased from Nanjing Jiancheng Bioengineering Institute.
[0026] 1.3 Experimental instruments: Intelligent cell imaging system, Thermo Fisher Scientific Inc.; Multifunctional microwell reader, Thermo Fisher Scientific Inc.
[0027] 2 Experimental methods
[0028] 2.1 Solution preparation
[0029] 1% pentobarbital solution: Accurately weigh 1g of pentobarbital, add appropriate amount of distilled water to dissolve it, and then make up to volume in a 100mL volumetric flask.
[0030] 4% paraformaldehyde solution: Accurately weigh 10 g of paraformaldehyde and place it in a beaker. Add 250 mL of PBS, heat and stir at 55°C, and after dissolving, cool to room temperature and make up the volume in a 250 mL volumetric flask.
[0031] 50% ethanol solution: Use a measuring cylinder to accurately measure 50 mL of anhydrous ethanol and 50 mL of distilled water, place them in a volumetric flask, cover the volumetric flask stopper, and gently shake the volumetric flask to fully mix the ethanol and water.
[0032] Test drug for the positive control group: Accurately weigh an appropriate amount of bifendate pellets and place them in an EP tube, and add 1% normal saline to prepare 50 mg / mL.
[0033] 1% carbon tetrachloride solution: Accurately measure 1 mL of carbon tetrachloride solution and add it to a 100 mL volumetric flask. Add vegetable oil to the mark. Cover the volumetric flask with the stopper and gently shake the volumetric flask to fully mix the carbon tetrachloride and oil.
[0034] Test drug of experimental group 1: The granules of Example 1 were taken and 1% saline was added to prepare 3 g crude drug / mL of the test drug.
[0035] Test drug of experimental group 2: The granules of Example 2 were taken and 1% saline was added to prepare 3 g crude drug / mL of the test drug.
[0036] Test drug of experimental group 3: The granules of Example 3 were taken and 1% saline was added to prepare 3 g crude drug / mL of the test drug.
[0037] 2.2 Efficacy of the test drugs on cisplatin-induced acute liver injury
[0038] (1) Grouping and administration: 36 male ICR mice were randomly divided into 6 groups. The blank control group and the model group were given corresponding volumes of saline by gavage for 14 consecutive days; the positive control group: bifendate drops were given by gavage at a dose of 0.15 g / kg for 14 consecutive days; experimental group 1: experimental group 1 drug solution was given by gavage at a dose of 16 g crude drug / kg for 14 consecutive days; experimental group 2: experimental group 2 drug solution was given by gavage at a dose of 16 g crude drug / kg for 14 consecutive days; experimental group 3: experimental group 3 drug solution was given by gavage at a dose of 16 g crude drug / kg for 14 consecutive days. On the 15th day, except for the blank control group, the other groups were intraperitoneally injected with 25 mg / kg cisplatin solution for modeling; 72 hours later, the mice in each group were anesthetized with 1% pentobarbital, and blood was collected by removing the eyeballs, and the blood was put into a blood collection tube treated with sodium heparin, centrifuged at 3000 rpm for 10 minutes, and plasma was collected for later use; the liver tissue was removed and weighed, and then stored in 4% paraformaldehyde.
[0039] (2) Detection of related indicators: The liver coefficient of each group of mice was calculated (liver coefficient = liver tissue weight / mouse body weight × 100%); plasma samples were taken from each group of mice and the ALT and AST levels in the serum of each group of mice were detected according to the instructions of the ALT and AST kits; liver tissues of each group of mice were taken and sent to the company for HE staining observation.
[0040] 2.3 Efficacy of the tested drugs on acute liver injury induced by carbon tetrachloride
[0041] (1) Grouping and administration: 36 male ICR mice were randomly divided into 6 groups. The blank control group and the model group were given corresponding volumes of saline by gavage for 30 consecutive days; the positive control group: bifendate drops were given by gavage at a dose of 0.15 g / kg for 30 consecutive days; experimental group 1: experimental group 1 drug solution was given by gavage at a dose of 16 g crude drug / kg for 30 consecutive days; experimental group 2: experimental group 2 drug solution was given by gavage at a dose of 16 g crude drug / kg for 30 consecutive days; experimental group 3: experimental group 3 drug solution was given by gavage at a dose of 16 g crude drug / kg for 30 consecutive days. On the 31st day, except for the blank control group, the other groups were intraperitoneally injected with 1% carbon tetrachloride at a dose of 20 mg / kg for modeling; 48 hours later, the mice in each group were anesthetized with 1% pentobarbital, and blood was collected by removing the eyeballs, and the blood was put into a blood collection tube treated with sodium heparin, centrifuged at 3000 rpm for 10 minutes, and plasma was collected for later use; the liver tissue was removed and weighed, and then stored in 4% paraformaldehyde.
[0042] (2) Detection of related indicators: The liver coefficient of each group of mice was calculated (liver coefficient = liver tissue weight / mouse body weight × 100%); plasma samples were taken from each group of mice and the ALT and AST levels in the serum of each group of mice were detected according to the instructions of the ALT and AST kits; liver tissues of each group of mice were taken and sent to the company for HE staining observation.
[0043] 2.4 Efficacy of the tested drugs on alcohol-induced acute liver injury
[0044] (1) Grouping and administration: 36 male ICR mice were randomly divided into 6 groups. The blank control group and the model group were given corresponding volumes of saline by gavage for 30 consecutive days; the positive control group: bifendate drops were given by gavage at a dose of 0.15 g / kg for 30 consecutive days; experimental group 1: experimental group 1 drug solution was given by gavage at a dose of 16 g crude drug / kg for 30 consecutive days; experimental group 2: experimental group 2 drug solution was given by gavage at a dose of 16 g crude drug / kg for 30 consecutive days; experimental group 3: experimental group 3 drug solution was given by gavage at a dose of 16 g crude drug / kg for 30 consecutive days. On the 31st day, except for the blank control group, the other groups were given 50% ethanol solution by gavage at a dose of 12 mL / kg for modeling; 24 hours later, the mice in each group were anesthetized with 1% pentobarbital, and blood was collected by removing the eyeballs, and the blood was put into a blood collection tube treated with sodium heparin, centrifuged at 3000 rpm for 10 min, and plasma was collected for later use; the liver tissue was taken out and weighed, and then stored in 4% paraformaldehyde.
[0045] (2) Detection of related indicators: The liver coefficient of each group of mice was calculated (liver coefficient = liver tissue weight / mouse body weight × 100%); plasma samples were taken from each group of mice and the ALT and AST levels in the serum of each group of mice were detected according to the instructions of the ALT and AST kits; kidney tissues of each group of mice were taken and sent to the company for HE staining observation.
[0046] 2.5 Statistical methods
[0047] The results were expressed as mean ± SD and analyzed using GraphPad Prism 5 statistical software. One-way ANOVA was used to compare the differences among the groups. P < 0.05 indicated statistically significant differences.
[0048] 3 Results and discussion
[0049] 3.1 The preventive and therapeutic effects of the test drugs on mice with acute liver injury induced by cisplatin
[0050] The experimental results of the effect on the liver coefficient are shown in Table 1. Compared with the blank control group, the liver coefficient of the model group was significantly increased (P < 0.001). Compared with the model group, the liver coefficients of the positive control group and experimental groups 1-3 were significantly reduced (P < 0.01). Compared with the positive control group, there was no significant difference in the liver coefficients of experimental groups 1-3 (P > 0.05), and the liver coefficient of experimental group 1 was the lowest. The above results show that intraperitoneal injection of cisplatin can significantly cause acute liver damage. Experimental groups 1-3 can relieve liver edema or congestion caused by cisplatin, and experimental group 1 (optimal ratio) has the best therapeutic effect.
[0051] Table 1 Liver coefficient values of animals in each group (n=6)
[0052] Group Organ coefficient (%) Blank control group <![CDATA[4.06±0.17 *** ]]> Model Group 5.40±0.24 Positive control group <![CDATA[4.61±0.28 ** ]]> Experimental Group 1 <![CDATA[4.58±0.11 **ns ]]> Experimental Group 2 <![CDATA[4.81±0.15 **ns ]]> Experimental Group 3 <![CDATA[4.91±0.81 **ns ]]>
[0053] Note: Compared with the model group, ***P<0.001, **P<0.01; compared with the positive control group, ns P>0.05.
[0054] The experimental results of the effect on liver function are shown in Table 2. Compared with the blank control group, the ALT and AST levels in the model group were significantly increased (P < 0.001), while compared with the model group, the AST and ALT levels in the positive control group and experimental groups 1-3 were significantly decreased (P < 0.001). There was no significant difference in AST content between experimental groups 1-3 and the positive control group (P > 0.05), and there was no significant difference in ALT content between experimental group 1 and the positive control group (P > 0.05). The above results show that intraperitoneal injection of cisplatin can significantly increase the levels of AST and ALT in plasma. Experimental groups 1-3 can alleviate the increase in AST and ALT levels caused by cisplatin, and experimental group 1 (optimal ratio) has the best therapeutic effect.
[0055] Table 2 AST and ALT levels in plasma samples of animals in each group (n=6)
[0056] Group AST(U / L) ALT(U / L) Blank control group <![CDATA[35.15±10.63 *** ]]> <![CDATA[18.33±2.39 *** ]]> Model Group 131.82±41.50 87.28±12.37 Positive control group <![CDATA[47.61±10.15 *** ]]> <![CDATA[33.88±4.83 *** ]]> Experimental Group 1 <![CDATA[54.24±15.71 ***ns ]]> <![CDATA[37.37±4.08 ***ns ]]> Experimental Group 2 <![CDATA[63.80±9.74 ***ns ]]> <![CDATA[46.60±7.82 *** ]]> Experimental Group 3 <![CDATA[75.49±37.96 ***ns ]]> <![CDATA[56.11±14.78 *** ]]>
[0057] Note: ***P<0.001 compared with the model group; ns P>0.05 compared with the positive control group.
[0058] The experimental results on the effect on liver tissue morphology are as follows Figure 1 As shown, the blank control group had a clear liver tissue cell structure, neatly arranged and regular, and the cells were plump and undamaged; the liver tissue structure was abnormal, and necrotic foci were visible in the lobules. The liver tissue damage in the positive control group and each drug-treated group was significantly alleviated, as shown by the neat arrangement of the liver tissue structure and the significant reduction in the area of necrotic foci in the lobules. And compared with the liver tissue pathological damage degree of experimental group 1 and experimental groups 2 and 3, the damage degree of experimental groups 2 and 3 was significantly greater than that of experimental group 1. In summary, experimental groups 1-3 can effectively alleviate liver damage caused by cisplatin, and experimental group 1 (optimal ratio) has the best therapeutic effect.
[0059] 3.2 The effect of the tested drugs on the prevention and treatment of acute liver injury induced by carbon tetrachloride in mice
[0060] The experimental results of the effect on the liver coefficient are shown in Table 3. Compared with the blank control group, the liver coefficient of the model group increased significantly (P < 0.001), and compared with the model group, the liver coefficients of the positive control group and experimental groups 1-3 were significantly reduced (P < 0.001, P < 0.01). Compared with the positive control group, there was no significant difference in the liver coefficients of experimental groups 1-3 (P > 0.05). The above results show that experimental groups 1-3 can alleviate liver edema or congestion caused by carbon tetrachloride.
[0061] Table 3 Liver coefficient values of animals in each group (n=6)
[0062]
[0063]
[0064] Note: Compared with the model group, ***P<0.001, **P<0.01; compared with the positive control group, ns P>0.05.
[0065] The experimental results of the effect on liver function are shown in Table 4. Compared with the model group and the blank control group, the ALT and AST levels were significantly increased (P < 0.001), while the positive control group and experimental groups 1-3 were significantly reduced compared with the model group (P < 0.001, P < 0.01). Compared with the positive control group, there was no significant difference in the AST and ALT levels of experimental groups 1-3 (P > 0.05), and the AST and ALT levels in plasma of experimental group 1 were the lowest. In summary, the results show that carbon tetrachloride can significantly increase the AST and ALT levels in plasma after induction. Experimental groups 1-3 can alleviate the increase in AST and ALT levels caused by carbon tetrachloride, and experimental group 1 (optimal ratio) has the best therapeutic effect.
[0066] Table 4 AST and ALT levels in plasma samples of animals in each group (n = 6)
[0067] Group AST(U / L) ALT(U / L) Blank control group <![CDATA[21.98±6.84 *** ]]> <![CDATA[21.21±3.58 *** ]]> Model Group 132.65±32.21 87.51±15.49 Positive control group <![CDATA[64.93±24.13 *** ]]> <![CDATA[50.62±14.05 *** ]]> Experimental Group 1 <![CDATA[57.25±11.13 ***ns ]]> <![CDATA[53.22±10.21 ***ns ]]> Experimental Group 2 <![CDATA[70.48±15.11 ***ns ]]> <![CDATA[55.71±10.86 ***ns ]]> Experimental Group 3 <![CDATA[88.51±33.25 **ns ]]> <![CDATA[60.57±12.97 **ns ]]>
[0068] Note: Compared with the model group, ***P<0.001, **P<0.01; compared with the positive control group, ns P>0.05.
[0069] The experimental results on the effect on liver tissue morphology are as follows Figure 2As shown in the figure, the liver tissue cell structure of the blank control group was clear, arranged neatly and regularly, and the cells were plump and undamaged; the liver tissue structure of the model group was severely abnormal, with large areas of necrotic foci visible in the lobules, the contours of the hepatocytes disappeared in the necrotic foci, the nuclei were fragmented or dissolved, and only red homogenous structures were seen. The liver tissue damage in the positive control group and experimental groups 1-3 was significantly alleviated, specifically manifested in the neat arrangement of the liver tissue structure, the significant reduction in the area of necrotic foci in the lobules, and the significant reduction in the degree of hepatocyte necrosis. Compared with the degree of liver tissue pathological damage in experimental group 1 and experimental groups 2 and 3, the area of necrotic foci in the lobules of experimental groups 2 and 3 was significantly greater than that of experimental group 1. In summary, experimental groups 1-3 can effectively alleviate liver damage caused by carbon tetrachloride, and experimental group 1 (optimal ratio) has the best efficacy.
[0070] 3.3 The preventive and therapeutic effects of the tested drugs on mice with alcohol-induced acute liver injury
[0071] The experimental results of the effect on the liver coefficient are shown in Table 5. Compared with the blank control group, the model group had a significantly increased liver coefficient (P < 0.001). Compared with the model group, the positive control group and experimental groups 1-3 had significantly decreased liver coefficients (P < 0.001). Compared with the positive control group, there was no significant difference in liver coefficients between experimental groups 1-3 (P > 0.05), and the liver coefficient of experimental group 1 was the lowest. The above results show that consuming a large amount of alcohol can significantly cause acute liver damage. Both the control group and experimental groups 1-3 can relieve liver edema or congestion caused by alcohol, and experimental group 1 (optimal ratio) has the best therapeutic effect.
[0072] Table 5 Liver coefficient values of animals in each group (n=6)
[0073] Group Organ coefficient (%) Blank control group <![CDATA[3.94±0.21 *** ]]> Model Group 4.84±0.14 Positive control group <![CDATA[4.14±0.14 *** ]]> Experimental Group 1 <![CDATA[4.04±0.16 ***ns ]]> Experimental Group 2 <![CDATA[4.10±0.16 ***ns ]]> Experimental Group 3 <![CDATA[4.14±0.17 ***ns ]]>
[0074] Note: ***P<0.001 compared with the model group; ns P>0.05 compared with the positive control group.
[0075] The experimental results of the effect on liver function are shown in Table 6. Compared with the model group and the blank control group, the ALT and AST levels were significantly increased (P < 0.001), while the AST and ALT levels in the positive control group and experimental groups 1-3 were significantly reduced compared with the model group (P < 0.001). There was no significant difference in the AST and ALT levels between experimental groups 1-2 and the positive control group (P > 0.05), and the AST and ALT levels in plasma of experimental group 1 were the lowest. The above results show that the intake of a large amount of alcohol can significantly increase the AST and ALT levels in plasma. Both the control group and experimental groups 1-3 can alleviate the increase in AST and ALT levels caused by alcohol, and experimental group 1 (optimal ratio) has the best therapeutic effect.
[0076] Table 6 AST and ALT levels in plasma samples of animals in each group (n=6)
[0077] Group AST(U / L) ALT(U / L) Blank control group <![CDATA[25.88±4.37 *** ]]> <![CDATA[18.52±4.03 *** ]]> Model Group 89.79±11.12 74.56±8.67 Positive control group <![CDATA[41.77±8.21 *** ]]> <![CDATA[36.33±13.32 *** ]]> Experimental Group 1 <![CDATA[39.89±8.23 ***ns ]]> <![CDATA[38.76±9.49 ***ns ]]> Experimental Group 2 <![CDATA[51.83±13.91 ***ns ]]> <![CDATA[42.50±8.74 ***ns ]]> Experimental Group 3 <![CDATA[61.08±11.85 *** ]]> <![CDATA[50.16±7.93 *** ]]>
[0078] Note: ***P<0.001 compared with the model group; ns P>0.05 compared with the positive control group.
[0079] The experimental results on the effect on liver tissue morphology are as follows Figure 3 As shown, the blank control group had a clear liver tissue cell structure, neatly arranged, and plump cells without damage; the model group had fatty degeneration of the liver, and clearly defined lipid droplet vacuoles appeared in the cytoplasm of the liver cells. The fatty degeneration of the liver in the positive control group and experimental groups 1-3 was significantly improved. The above results show that experimental groups 1-3 can effectively alleviate alcohol-induced liver damage.
[0080] 3.4 Conclusion
[0081] In three chemical liver injury models, mice treated with the drug of the present invention can significantly inhibit liver edema or congestion, and inhibit the increase of ALT and AST levels, and have a significant protective effect against liver injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1 HE-stained microscopic images of liver tissues of mice in each group in the cisplatin model (200 times field of view).
[0083] Figure 2 HE-stained microscopic images of liver tissues of mice in each group in the carbon tetrachloride model (200 times field of view).
[0084] Figure 3 HE-stained microscopic images of liver tissues of mice in each group in the alcohol model (200 times field of view). DETAILED DESCRIPTION
[0086] Example 1 (granules)
[0087] 1. Prescription:
[0088] 120g ginseng, 360g astragalus, 120g turmeric, 240g kudzu root, 120g platycodon, and 120g licorice.
[0089] 2. Preparation method:
[0090] (1) Accurately weigh the above raw materials and place them in a traditional Chinese medicine frying pan, add 11 times water and soak for 1.5 hours, boil over high heat and then simmer over low heat for 1.5 hours, then filter and collect the first decoction;
[0091] (2) Add 8 times more water to the residue, boil over high heat, then simmer over low heat for 50 min, filter, and collect the second decoction;
[0092] (3) combining the two decoctions, evaporating and concentrating to a concentrate of 1 g crude drug / mL, and drying to obtain the active ingredient;
[0093] (4) Take the active ingredient obtained in step (3), add appropriate amounts of sucrose and dextrin to 300 g, add appropriate amount of water to make granules, then dry and granulate, and package into 15 g / bag.
[0094] Example 2 (granules)
[0095] 1. Prescription:
[0096] Ginseng 140g, Astragalus 371g, Turmeric 123g, Pueraria lobata 231g, Platycodon 102g, Licorice 113g.
[0097] 2. Preparation method:
[0098] (1) Accurately weigh the above raw materials and place them in a traditional Chinese medicine frying pan, add 8 times the amount of water and soak for 2 hours, boil over high heat and then simmer over low heat for 1 hour, then filter and collect the first decoction;
[0099] (2) Add 6 times more water to the residue, boil over high heat, then simmer over low heat for 40 min, filter, and collect the second decoction;
[0100] (3) combining the two decoctions, evaporating and concentrating to a concentrate of 1 g crude drug / mL, and drying to obtain the active ingredient;
[0101] (4) Take the active ingredient obtained in step (3), add appropriate amounts of sucrose and dextrin to 300 g, add appropriate amount of water to make granules, then dry and granulate, and package into 15 g / bag.
[0102] Example 3 (granules)
[0103] 1. Prescription:
[0104] 98g ginseng, 367g astragalus, 140g turmeric, 248g kudzu root, 119g platycodon, and 108g licorice.
[0105] 2. Preparation method:
[0106] (1) Accurately weigh the above raw materials and place them in a traditional Chinese medicine frying pan, add 12 times the amount of water and soak for 1 hour, boil over high heat and then simmer over low heat for 2 hours, then filter and collect the first decoction;
[0107] (2) Add 10 times the amount of water to the residue, boil over high heat, then simmer over low heat for 60 min, filter, and collect the second decoction;
[0108] (3) combining the two decoctions, evaporating and concentrating to a concentrate of 1 g crude drug / mL, and drying to obtain the active ingredient;
[0109] (4) Take the active ingredient obtained in step (3), add appropriate amounts of sucrose and dextrin to 300 g, add appropriate amount of water to make granules, then dry and granulate, and package into 15 g / bag.
[0110] Embodiment 4 (capsule)
[0111] The drug particles prepared according to the method of Example 1 were loaded into hollow capsules, with each capsule containing 0.8 g, to prepare capsules.
[0112] Example 5 (Tablet)
[0113] The drug particles prepared according to the method of Example 1 were compressed and coated to form tablets with a core weight of 0.8 g.
[0114] Embodiment 6 (oral liquid)
[0115] 1. Prescription:
[0116] 120g ginseng, 360g astragalus, 120g turmeric, 240g kudzu root, 120g platycodon, and 120g licorice.
[0117] 2. Preparation method:
[0118] (1) Accurately weigh the above raw materials and place them in a traditional Chinese medicine frying pan, add 12 times water and soak for 1 hour, boil over high heat and then simmer over low heat for 1 hour, then filter and collect the first decoction;
[0119] (2) Add 10 times more water to the residue, boil over high heat, then simmer over low heat for 40 min, filter, and collect the second decoction;
[0120] (3) Combine the two decoctions, evaporate and concentrate to a concentrate of 1 g crude drug / mL, select 0.03% xanthan gum, 0.1% pectin, and 0.1% soluble soybean polysaccharide by volume, mix them evenly to make them swell, heat and dissolve, mix them with the concentrate, add 0.1% mogroside, 0.05% citric acid, and 0.05% salt, and can them and sterilize them. Each bottle has a specification of 60 mL.
Claims
1. Use of a drug for preventing and treating deafness in the preparation of a drug for preventing and treating chemical liver damage, wherein: The active ingredients of the drug for preventing and treating chemical liver damage are made of the following raw materials in percentage by weight: Ginseng 9-13%, Astragalus 31-35%, Turmeric 9-13%, Pueraria 20-24%, Platycodon 9-13%, Licorice 9-13%; The chemical liver injury is chemical liver injury caused by cisplatin, carbon tetrachloride or alcohol.
2. The use according to claim 1, characterized in that: The active ingredient is made of the following raw materials in percentage by weight: Ginseng 11.1%, Astragalus 33.3%, Turmeric 11.1%, Pueraria lobata 22.2%, Platycodon 11.1%, Licorice 11.2%.
3. The use according to claim 1 or 2, characterized in that: The active ingredient is prepared by the following method: (1) placing the raw drug in a traditional Chinese medicine frying pan, adding 8-12 times water to soak for 1-2 hours, boiling over high heat, then decocting over low heat for 1-2 hours, then filtering and collecting the first decoction; (2) Add 6-10 times more water to the residue, boil over high heat, then simmer over low heat for 40-60 min, filter, and collect the second decoction; (3) The two decoctions are combined, evaporated and concentrated to a concentrate with a concentration of 1 g crude drug / mL, and dried to obtain the active ingredient.
4. The use according to claim 3, characterized in that: The medicine for preventing and treating chemical liver damage is in the form of granules, tablets, capsules or oral liquid.
Citation Information
Patent Citations
Oral suspension of standardized extract obtained from the roots of Panax ginseng CA Meyer containing at least 10% ginsenosides, for maintaining hepatocellular integrity in cases of steatohepatitis associated with obesity and metabolic syndrome.
BR102012020215A2
Composition with auxiliary protection effect on chemical hepatic injury and alcoholic hepatic injury and health care food thereof
CN102160637A
